Sign In
Buy JEF
$52.84
-1.41 (-2.59%)
At Close: Jun 03, 2026
Jefferies Financial Group Inc. $JEF Shares Sold by Creative Planning
03:57am, Tuesday, 25'th Nov 2025
Creative Planning trimmed its holdings in shares of Jefferies Financial Group Inc. (NYSE: JEF) by 3.8% during the second quarter, according to the company in its most recent Form 13F filing with the S
New York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point B
NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital
Court orders independent probe into First Brands fraud allegations
06:09pm, Wednesday, 19'th Nov 2025
A U.S. bankruptcy judge on Wednesday ordered an independent investigation into auto parts maker First Brands, allocating a $7 million budget to probe allegations of fraud involving the company's use o
JEF STOCK: Jefferies Financial Group Inc. Investigated for Securities Fraud after 8% Stock Drop -- Investors Notified to Contact BFA Law
08:08am, Wednesday, 19'th Nov 2025
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital
Saga Diagnostics to Present at Jefferies Global Healthcare Conference in London
07:00am, Tuesday, 18'th Nov 2025
MORRISVILLE, N.C.--(BUSINESS WIRE)-- #JefferiesHealthcare--Presentation will focus on its flagship MRD assay, Pathlight, accompanied by a commercial update following its favorable Medicare coverage.
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital
Vicore to Present at The Jefferies Global Healthcare Conference in London
02:20am, Monday, 17'th Nov 2025
STOCKHOLM, SE / ACCESS Newswire / November 17, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), t
Walmart has a conducive story to continued sales growth, says Jefferies' Corey Tarlowe
03:05pm, Friday, 14'th Nov 2025
Corey Tarlowe, Jefferies analyst, joins 'Power Lunch' to discuss the executive shakeup at Walmart, the company's same-store sales growth and much more.
New York, New York--(Newsfile Corp. - November 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point B
Expecting the longest run of earnings growth in the energy sector: Jefferies' Julien Dumoulin-Smith
04:43pm, Thursday, 13'th Nov 2025
Julien Dumoulin-Smith, Jefferies analyst, joins 'Power Lunch' to discuss how AI will impact the energy sector, if utilities are given money back to customers and much more.
Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025)
12:00pm, Thursday, 13'th Nov 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overv
Jefferies Group's Strategic Move: Vanguard Information Technology ETF Takes Center Stage
11:03am, Thursday, 13'th Nov 2025
Jefferies Group (Trades, Portfolio)'s Latest 13F Filing Reveals Strategic Portfolio Adjustments Jefferies Group (Trades, Portfolio) recently submitted its 13F
Keenova to Participate in the Jefferies Global Healthcare Conference in London
04:00pm, Wednesday, 12'th Nov 2025
DUBLIN , Nov. 12, 2025 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today announced that management will present at the Jefferies Global Healthcare Conference in London on Wed
Jefferies' David Zervos: Revisions are the story of the year in the data market
11:12am, Wednesday, 12'th Nov 2025
David Zervos, Jefferies chief market strategist, joins CNBC's 'Squawk on the Street' to discuss macro outlooks, expectations for the Fed, and much more.
